(Alliance News) - Horizon Discovery Group PLC on Wednesday said its Chosource platform supports the development of immunotherapy for autoimmune diseases.
The Chosource platform is Horizon's "royalty-free alternative for the production of complex proteins" and has been used for "multiple successful Innovative New Drug filings".
The gene editing and gene modulation technologies company said the platform helped to generate a stable cell line for the development of a treatment for autoimmune diseases such as inflammatory bowel diseases, rheumatoid arthritis, and multiple sclerosis.
Horizon said its gene-edited glutamine synthetase knockout CHO K1 cell line expression system was used to generate a high yielding cell line for Immutep's IMP761 product candidate, an agonist antibody targeting the immune checkpoint lymphocyte activation gene LAG-3.
LAG-3 controls the signalling between specific immune cells, T cells and antigen presenting cells, which are responsible for the adaptive immune response.
Horizon added that Chosource includes a gene-edited cell line which has been recognised as "suitable for high yield biomanufacturing" by both regulators and the industry.
"We are dedicated to ensuring availability of key technologies that can improve affordability of medicines worldwide. Our Chosource biomanufacturing platform is empowering organizations from early stage start-ups to large pharmaceutical companies to drive efficiencies throughout development and production and has already been utilized in multiple successful innovative new drug filings," said Horizon Chief Executive Terry Pizzie.
The stock was trading 1.7% lower at 112.50 pence each on Wednesday afternoon in London.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
